|
Index of reports
> Death (2)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Trilipix (Fenofibrate) death. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Trilipix side effects in male
Reported by a consumer/non-health professional from United States on 2012-02-20
Patient: male
Reactions: Ischaemic Cardiomyopathy, Dyspnoea, Dementia, Hypophagia, Coronary Artery Occlusion, Renal Failure Chronic, Myocardial Infarction
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Niaspan
Administration route: Oral
Indication: High Density Lipoprotein Decreased
End date: 2012-02-04
Trilipix
Indication: LOW Density Lipoprotein Increased
Niaspan
Indication: LOW Density Lipoprotein Increased
Trilipix
Administration route: Oral
Indication: High Density Lipoprotein Decreased
End date: 2012-02-04
Other drugs received by patient: Spiriva; Unknown Nebulization Medication; Imdur; Haloperidol; Hydralazine HCL; Unknown Inhaler; Carvedilol; Citalopram Hydrobromide
Possible Trilipix side effects in 57 year old male
Reported by a physician from United States on 2012-02-07
Patient: 57 year old male, weighing 113.4 kg (249.5 pounds)
Reactions: Pancreatitis Necrotising, Acute Respiratory Distress Syndrome, Renal Failure Acute
Adverse event resulted in: death
Drug(s) suspected as cause:
Trilipix
Other drugs received by patient: Simvastatin
|
